Sign Up to like & get
recommendations!
0
Published in 2020 at "Schizophrenia Bulletin"
DOI: 10.1093/schbul/sbaa029.765
Abstract: Abstract Background Standard of care (SOC) antipsychotics exhibit efficacy at high dopamine D2 receptor occupancy (60%-80%), which is associated with increased risk of extrapyramidal symptoms (EPS). Lumateperone (lumateperone tosylate, ITI-007) is a mechanistically novel antipsychotic…
read more here.
Keywords:
schizophrenia;
eps related;
long term;
treatment ... See more keywords